NCT04556539View on ClinicalTrials.gov

Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Advanced Ovarian Cancer
Interventions
DRUG

SC10914

400mg TID, oral admination on fasting condition

Trial Locations (1)

Unknown

RECRUITING

Fujian Cancer Hospital, Fujian

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY

NCT04556539 - Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter